Jefferies Group reissued their hold rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report published on Friday. The brokerage currently has a $421.00 price objective on the biopharmaceutical company’s stock. Jefferies Group also issued estimates for Regeneron Pharmaceuticals’ FY2019 earnings at $15.91 EPS, FY2020 earnings at $17.62 EPS and FY2021 earnings at $21.92 EPS.

A number of other research analysts also recently weighed in on the company. Zacks Investment Research downgraded Regeneron Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, October 10th. Morgan Stanley reiterated an equal weight rating and set a $490.00 target price (up previously from $450.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. JPMorgan Chase & Co. reiterated a hold rating on shares of Regeneron Pharmaceuticals in a report on Monday, October 16th. Canaccord Genuity reiterated a buy rating on shares of Regeneron Pharmaceuticals in a report on Monday, October 16th. Finally, Barclays downgraded Regeneron Pharmaceuticals from an equal weight rating to an underweight rating and reduced their target price for the stock from $450.00 to $395.00 in a report on Friday, October 20th. Three investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eleven have assigned a buy rating to the company. The stock has an average rating of Hold and a consensus price target of $468.15.

Regeneron Pharmaceuticals (REGN) traded up $0.25 on Friday, reaching $346.04. The company’s stock had a trading volume of 1,419,513 shares, compared to its average volume of 881,032. The company has a market cap of $37,151.33, a price-to-earnings ratio of 31.43, a price-to-earnings-growth ratio of 1.33 and a beta of 1.47. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07. Regeneron Pharmaceuticals has a fifty-two week low of $340.65 and a fifty-two week high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, beating analysts’ consensus estimates of $3.83 by $0.16. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. Regeneron Pharmaceuticals’s quarterly revenue was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.13 EPS. analysts anticipate that Regeneron Pharmaceuticals will post 13.55 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of REGN. Steward Partners Investment Advisory LLC grew its stake in shares of Regeneron Pharmaceuticals by 495.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 307 shares during the last quarter. Vident Investment Advisory LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $200,000. Virtu KCG Holdings LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $206,000. Moors & Cabot Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $217,000. Finally, People s United Financial Inc. grew its stake in shares of Regeneron Pharmaceuticals by 656.7% in the 2nd quarter. People s United Financial Inc. now owns 454 shares of the biopharmaceutical company’s stock worth $223,000 after buying an additional 394 shares during the last quarter. Institutional investors own 66.82% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2018/02/03/regeneron-pharmaceuticals-regn-stock-rating-reaffirmed-by-jefferies-group.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.